# Sarepta (SRPT) — Earnings

SRPT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/srpt/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.05 |
| EPS estimate | $0.22 |
| EPS surprise | −123.01% |
| Revenue surprise | +9.51% |
| Revenue | $401.3M |
| Revenue estimate | $366.4M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/873303/000119312526335003/srpt-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/1efa19d5-6455-eca2-075e-ca8b5edd4963.html) |

Sarepta reported Q2 2026 results on August 5, 2026. It posted a loss of $0.05 per share, against an expected profit of $0.22, a 123.01% miss. Revenue was $401.3 million, 9.51% above the $366.4 million estimate. A year earlier, Q2 2025 showed EPS of $1.89 on $611.1 million in revenue, so sales fell about 34%.

Results swing widely in the table. Annual losses were $8.03 per share in 2022 and $6.12 in 2023. Fiscal 2024 was the only full year shown with a profit, at $2.28, before a loss of $8.44 in 2025. Yearly revenue, by contrast, grew from $933.0 million in 2022 to $2.20 billion in 2025. The largest quarterly loss in the table was $5.86 per share, in Q1 2023. The first half of 2026 shows a profit of $2.83 per share against a loss of $2.71 a year earlier, on revenue down about 16.5%. Sarepta beat the EPS estimate in 11 of the last 20 quarters, but only once in the last four.

Q3 results came out between November 1 and November 6 in each of the past five years. That points to early November 2026 for the next report.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | $0.22 | −$0.05 | -123.01% | $366.4M | $401.3M |
| Q1 2026 | May 6, 2026 | $0.98 | $2.88 | 195.11% | $474.2M | $730.8M |
| Q4 2025 | Feb 25, 2026 | −$1.20 | −$3.93 | -228.27% | $369.6M | $442.9M |
| Q3 2025 | Nov 3, 2025 | −$0.73 | −$1.80 | -147.59% | $335.8M | $399.4M |
| Q2 2025 | Aug 6, 2025 | $0.83 | $1.89 | 127.08% | $530.7M | $611.1M |
| Q1 2025 | May 6, 2025 | −$3.21 | −$4.60 | -43.44% | $687.5M | $744.9M |
| Q4 2024 | Feb 26, 2025 | $1.88 | $1.50 | -20.32% | $627.6M | $658.4M |
| Q3 2024 | Nov 6, 2024 | −$0.08 | $0.34 | 550.33% | $407.2M | $467.2M |
| Q2 2024 | Aug 7, 2024 | −$0.13 | $0.07 | 154.05% | $394.4M | $362.9M |
| Q1 2024 | May 1, 2024 | $0.01 | $0.37 | 2768.22% | $379.5M | $413.5M |
| Q4 2023 | Feb 28, 2024 | $0.07 | $0.47 | 582.15% | $387.2M | $396.8M |
| Q3 2023 | Nov 1, 2023 | −$1.22 | −$0.46 | 62.39% | $285.3M | $331.8M |
| Q2 2023 | Aug 2, 2023 | −$1.78 | −$0.27 | 84.80% | $256.0M | $261.2M |
| Q1 2023 | May 2, 2023 | −$1.29 | −$5.86 | -353.07% | $241.9M | $253.5M |
| Q4 2022 | Feb 28, 2023 | −$1.47 | −$1.24 | 15.86% | $250.4M | $258.4M |
| Q3 2022 | Nov 2, 2022 | −$1.22 | −$2.94 | -140.14% | $234.5M | $230.3M |
| Q2 2022 | Aug 2, 2022 | −$1.11 | −$2.65 | -139.08% | $220.8M | $233.5M |
| Q1 2022 | May 4, 2022 | −$1.31 | −$1.20 | 8.60% | $206.4M | $210.8M |
| Q4 2021 | Mar 1, 2022 | −$1.26 | −$1.42 | -13.14% | $198.0M | $201.5M |
| Q3 2021 | Nov 3, 2021 | −$1.79 | −$0.60 | 66.41% | $178.9M | $189.4M |

## Frequently Asked Questions

### When did Sarepta (SRPT) last report earnings?

Sarepta last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did SRPT beat earnings estimates?

No. Sarepta reported EPS of −$0.05 for Q2 2026 against a $0.22 estimate — a 123.01% miss.

### How much revenue did SRPT report last quarter?

Sarepta reported $401.3M in revenue for Q2 2026, against a consensus estimate of $366.4M.

## Similar Stocks

- [EDIT](https://www.lighthorse.io/tickers/edit) — Editas Medicine, Inc. - Common Stock
- [CTMX](https://www.lighthorse.io/tickers/ctmx) — CytomX Therapeutics, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).